Society Pass shares fall 15.48% after-hours after announcing $3 million public offering of common stock.
ByAinvest
Wednesday, Feb 18, 2026 4:48 pm ET1min read
SOPA--
Society Pass Inc. (SOPA) fell 15.48% in after-hours trading, likely driven by its recent $3 million public offering of common stock. While the offering was priced at a premium under Nasdaq rules, the move may have raised concerns about capital dilution or market conditions, as the stock has trended downward (-12.82%) in multiple prior sessions. Despite a Zacks rating upgrade to "Buy" and several strategic partnerships in the travel and eSIM markets, the offering’s timing or execution appears to have overshadowed these positives. The prolonged negative momentum (-12.82% across multiple news dates) suggests investor skepticism about the company’s financial strategy or the value of its recent collaborations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet